1579939-43-7

Basic information

• Product Name: C₂₀H₂₂FN₅O₃S₂
• Synonyms: C₂₀H₂₂FN₅O₃S₂
• CAS NO: 1579939-43-7
• Molecular Weight: 463.557
• Mol File: 1579939-43-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₀H₂₂FN₅O₃S₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₀H₂₂FN₅O₃S₂(1579939-43-7)
• EPA Substance Registry System: C₂₀H₂₂FN₅O₃S₂(1579939-43-7)

Safety Data

• Hazardous Substances Data: 1579939-43-7(Hazardous Substances Data)

Upstream product

• 1579939-37-9 C₁₈H₂₁FN₄O₃S₂ 
• 1579939-36-8 C₁₁H₁₇N₃O₃S 
• 100371-33-3 4-tert-butylsulfamoyl-benzoic acid methyl ester 
• 99987-05-0 4-tert-butylsulfamoyl-benzoic acid 
• 130111-04-5 2-bromoacetaldehyde oxime 
• 1579939-39-1 C₁₈H₁₉FN₄O₂S₂ 

Downstream Products

• 1579939-44-8 4-(4-(4-fluorophenyl)-5-(2-(hydroxyimino)ethylthio)-4H-1,2,4-triazol-3-yl)benzenesulfonamide 
• 1579939-47-1 C₂₁H₂₅FN₆O₄S₂ 
• 1579939-48-2 4-(4-(4-fluorophenyl)-5-(2-(1-hydroxyureido)ethylthio)-4H-1,2,4-triazol-3-yl)benzenesulfonamide 

Relevant articles and documents

Discovery of potential anti-inflammatory drugs: Diaryl-1,2,4-triazoles bearing N-hydroxyurea moiety as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase

A series of hybrids from diaryl-1,2,4-triazole and hydroxamic acid or N-hydroxyurea were synthesized and evaluated as novel anti-inflammatory agents. The biological data showed that (i) all the compounds showed dual COX-2/5-LOX inhibitory activities in vitro, and 15e showed optimal inhibitory activities (COX-2: IC50 = 0.15 μM, 5-LOX: IC50 = 0.85 μM), (ii) 15e selectively inhibited COX-2 relative to COX-1 with selectivity index (SI = 0.012) comparable to celecoxib (SI = 0.015), (iii) 15e exhibited potent anti-inflammatory activity (inhibition: 54.1%) which was comparable to the reference drug celecoxib (inhibition: 46.7%) in a xylene-induced ear edema assay, and (iv) 15e displayed promising analgesic activity in acetic acid-induced writhing response and hot-plate assay. Finally, a molecular modeling study revealed the binding interactions of 15e with COX-2 and 5-LOX. Our findings suggest that 15e may be a promising anti-inflammatory agent for further evaluation.